☰

Moonsoo M. Jin - Publications

Affiliations: 
Cornell University, Ithaca, NY, United States 
Area:
Biomedical Engineering, Immunology, Biochemistry, Pharmaceutical Chemistry
Tree Info Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R, Choi YY, Cheong JH, Noh SH, Rha SY, Chung HC, ... Jin MM, et al. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Molecular Therapy Oncolytics. 18: 587-601. PMID 32995483 DOI: 10.1016/J.Omto.2020.08.009  0.368
2020 Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, van Basien K, Gaudet I, Law P, Kim NJ, von Hofe E, Jin MM. Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Scientific Reports. 10: 12733. PMID 32719389 DOI: 10.1038/S41598-020-69586-8  0.306
2020 Deh K, Zaman M, Vedvyas Y, Liu Z, Gillen KM, O' Malley P, Bedretdinova D, Nguyen T, Lee R, Spincemaille P, Kim J, Wang Y, Jin MM. Validation of MRI quantitative susceptibility mapping of superparamagnetic iron oxide nanoparticles for hyperthermia applications in live subjects. Scientific Reports. 10: 1171. PMID 31980695 DOI: 10.1038/S41598-020-58219-9  0.307
2020 Yang H, Puc J, Yang Y, McCloskey JE, Vedvyas Y, Li H, Min IM, Jin MM, Hofe Ev. Abstract LB-381: Mitigating on-target off-tumor cytotoxicity of EpCAM CAR-T by affinity tuning Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-381  0.399
2020 Yang Y, McCloskey JE, Yang H, Puc J, Gallegos AAG, Vedvyas Y, Min IM, Hofe Ev, Jin MM. Abstract 6598: Eradication of EpCAM expressing solid tumors by low-affinity CAR T cells Immunology. 80: 6598-6598. DOI: 10.1158/1538-7445.Am2020-6598  0.376
2020 Yang Y, McCloskey JE, Vedvyas Y, Min IM, Hofe Ev, Jin MM. Abstract 6597: Highly localized, inducible interleukin-12 release augments ICAM-1 CAR T cell activity against solid tumors Immunology. 80: 6597-6597. DOI: 10.1158/1538-7445.Am2020-6597  0.335
2019 Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, Besien KV, Gaudet I, Law P, Kim NJ, Hofe EV, Jin MM. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Scientific Reports. 9: 10634. PMID 31337787 DOI: 10.1038/S41598-019-46938-7  0.369
2019 Amor-Coarasa A, Kelly JM, Singh PK, Ponnala S, Nikolopoulou A, Williams C, Vedvyas Y, Jin MM, Warren JD, Babich JW. [F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4. Molecules (Basel, Switzerland). 24. PMID 31022852 DOI: 10.3390/Molecules24081612  0.312
2019 Jung M, Zaman M, Vedvyas Y, Zhang X, McCloskey JE, Yang Y, Min IM, Zamegar R, Choi YY, Cheong J, Noh SH, Rha SY, Chung HC, Jin MM. Abstract 1442: Chimeric antigen receptor T cell therapy targeting ICAM-1 in gastric cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1442  0.312
2019 Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Hsu YS, Hsu J, Besien KV, Gaudet I, Law P, Kim J, Hofe EV, Jin MM. Abstract 2329: Clinical manufacturing of CAR T cells targeting ICAM-1 for a phase I study against advanced thyroid cancer therapy Cancer Research. 79: 2329-2329. DOI: 10.1158/1538-7445.Am2019-2329  0.339
2019 Yang Y, Vedvyas Y, McCloskey JE, Min IM, Jin MM. Abstract 2322: ICAM-1 targeting CAR T cell therapy for triple negative breast cancer Cancer Research. 79: 2322-2322. DOI: 10.1158/1538-7445.Am2019-2322  0.356
2018 Vedvyas Y, McCloskey J, Yang Y, Min IM, Jin MM. Abstract 3592: Pharmacological intervention to temporally stimulate or inhibit ICAM-1 targeting CAR-T cells Cancer Research. 78: 3592-3592. DOI: 10.1158/1538-7445.Am2018-3592  0.4
2017 Park S, Shevlin E, Vedvyas Y, Zaman M, Park S, Hsu YS, Min IM, Jin MM. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Scientific Reports. 7: 14366. PMID 29085043 DOI: 10.1038/S41598-017-14749-3  0.377
2017 Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, Panjwani S, Gray KD, Tassler AB, Zarnegar R, Fahey TJ, ... Jin MM, et al. CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29025766 DOI: 10.1158/1078-0432.Ccr-17-2008  0.335
2017 Shevlin E, Park S, Vedvyas Y, Zaman M, Park S, Min IM, Jin MM. Abstract 3750: Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity Cancer Research. 77: 3750-3750. DOI: 10.1158/1538-7445.Am2017-3750  0.39
2017 Min IM, Vedvyas Y, Shevlin E, Zaman M, Wyrwas B, Wang W, Park S, Moore M, Scognamiglio T, Zarnegar R, Fahey TJ, Jin MM. Abstract 3624: CAR T cells targeting ICAM-1 trigger strong antitumor effects against advanced human thyroid tumors Endocrinology. 77: 3624-3624. DOI: 10.1158/1538-7445.Am2017-3624  0.345
2017 Vedvyas Y, Shevlin E, Zaman M, Min IM, Jin MM. Abstract 1707: Longitudinal and quantitative imaging of the localization, expansion, and contraction of tumor targeted adoptively transferred T cells Immunology. 77: 1707-1707. DOI: 10.1158/1538-7445.Am2017-1707  0.314
2016 Vedvyas Y, Shevlin E, Zaman M, Min IM, Amor-Coarasa A, Park S, Park S, Kwon KW, Smith T, Luo Y, Kim D, Kim Y, Law B, Ting R, Babich J, ... Jin MM, et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. Jci Insight. 1: e90064. PMID 27882353 DOI: 10.1172/Jci.Insight.90064  0.324
2015 Leelawattanachai J, Kwon KW, Michael P, Ting R, Kim JY, Jin MM. Side-by-Side Comparison of Commonly Used Biomolecules That Differ in Size and Affinity on Tumor Uptake and Internalization. Plos One. 10: e0124440. PMID 25901755 DOI: 10.1371/Journal.Pone.0124440  0.348
2014 Meng HW, Pagano JM, White BS, Toyoda Y, Min IM, Craighead HG, Shalloway D, Lis JT, Xiao K, Jin MM. Discovering aptamers by cell-SELEX against human soluble growth factors ectopically expressed on yeast cell surface. Plos One. 9: e93052. PMID 24675636 DOI: 10.1371/Journal.Pone.0093052  0.383
2013 Kang S, Lu K, Leelawattanachai J, Hu X, Park S, Park T, Min IM, Jin MM. Virus-mimetic polyplex particles for systemic and inflammation-specific targeted delivery of large genetic contents. Gene Therapy. 20: 1042-52. PMID 23759703 DOI: 10.1038/Gt.2013.29  0.738
2013 Park S, Kang S, Chen X, Kim EJ, Kim J, Kim N, Kim J, Jin MM. Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages. Biomaterials. 34: 598-605. PMID 23099063 DOI: 10.1016/J.Biomaterials.2012.10.004  0.737
2012 Kang S, Kim CU, Gu X, Owens RM, van Rijn SJ, Boonyaleepun V, Mao Y, Springer TA, Jin MM. Complex structure of engineered modular domains defining molecular interaction between ICAM-1 and integrin LFA-1. Plos One. 7: e44124. PMID 22956999 DOI: 10.1371/Journal.Pone.0044124  0.717
2012 Hu X, Saha P, Chen X, Kim D, Devarasetty M, Varadarajan R, Jin MM. Cell surface assembly of HIV gp41 six-helix bundles for facile, quantitative measurements of hetero-oligomeric interactions. Journal of the American Chemical Society. 134: 14642-5. PMID 22888993 DOI: 10.1021/Ja301099S  0.521
2012 Li J, Chang S, Liu T, Wang Q, Cui D, Chen X, Jin M, Wang B, Pei M, Wisnieff C, Spincemaille P, Zhang M, Wang Y. Reducing the object orientation dependence of susceptibility effects in gradient echo MRI through quantitative susceptibility mapping. Magnetic Resonance in Medicine. 68: 1563-9. PMID 22851199 DOI: 10.1002/Mrm.24135  0.468
2012 Gu X, Vedvyas Y, Chen X, Kaushik T, Hwang CI, Hu X, Nikitin AY, Jin MM. Novel strategy for selection of monoclonal antibodies against highly conserved antigens: phage library panning against ephrin-B2 displayed on yeast. Plos One. 7: e30680. PMID 22292016 DOI: 10.1371/Journal.Pone.0030680  0.54
2012 Wong R, Chen X, Wang Y, Hu X, Jin MM. Visualizing and quantifying acute inflammation using ICAM-1 specific nanoparticles and MRI quantitative susceptibility mapping. Annals of Biomedical Engineering. 40: 1328-38. PMID 22143599 DOI: 10.1007/S10439-011-0482-3  0.526
2011 Chen X, Wong R, Khalidov I, Wang AY, Leelawattanachai J, Wang Y, Jin MM. Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation. Biomaterials. 32: 7651-61. PMID 21783245 DOI: 10.1016/J.Biomaterials.2011.06.030  0.577
2011 Kang S, Park T, Chen X, Dickens G, Lee B, Lu K, Rakhilin N, Daniel S, Jin MM. Tunable physiologic interactions of adhesion molecules for inflamed cell-selective drug delivery. Biomaterials. 32: 3487-98. PMID 21306773 DOI: 10.1016/J.Biomaterials.2011.01.046  0.754
2011 Wong RL, Liu B, Zhu X, You L, Kong L, Han KP, Lee HI, Chavaillaz PA, Jin M, Wang Y, Rhode PR, Wong HC. Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules. Protein Engineering, Design & Selection : Peds. 24: 373-83. PMID 21177283 DOI: 10.1093/Protein/Gzq116  0.364
2011 Filicori F, Kang S, Buitrago D, Keutgen XM, Chen X, Hoda R, Veach A, Jin M, Fahey TJ, Zarnegar R. The I-domain, a multifaceted nanoparticle for targeting of poorly differentiated thyroid cancer Journal of the American College of Surgeons. 213: S143. DOI: 10.1016/J.Jamcollsurg.2011.06.350  0.735
2010 Park S, Kang S, Veach AJ, Vedvyas Y, Zarnegar R, Kim JY, Jin MM. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions. Biomaterials. 31: 7766-75. PMID 20667589 DOI: 10.1016/J.Biomaterials.2010.06.038  0.754
2010 Tremblay JM, Kuo CL, Abeijon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon : Official Journal of the International Society On Toxinology. 56: 990-8. PMID 20637220 DOI: 10.1016/J.Toxicon.2010.07.003  0.361
2010 Hu X, Kang S, Lefort C, Kim M, Jin MM. Combinatorial libraries against libraries for selecting neoepitope activation-specific antibodies. Proceedings of the National Academy of Sciences of the United States of America. 107: 6252-7. PMID 20308586 DOI: 10.1073/Pnas.0914358107  0.731
2010 Owens RM, Gu X, Shin M, Springer TA, Jin MM. Engineering of single Ig superfamily domain of intercellular adhesion molecule 1 (ICAM-1) for native fold and function. The Journal of Biological Chemistry. 285: 15906-15. PMID 20304924 DOI: 10.1074/Jbc.M110.104349  0.363
2009 Mao Y, Balkin DM, Zoncu R, Erdmann KS, Tomasini L, Hu F, Jin MM, Hodsdon ME, De Camilli P. A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism. The Embo Journal. 28: 1831-42. PMID 19536138 DOI: 10.1038/Emboj.2009.155  0.308
2009 Hu X, Kang S, Chen X, Shoemaker CB, Jin MM. Yeast surface two-hybrid for quantitative in vivo detection of protein-protein interactions via the secretory pathway. The Journal of Biological Chemistry. 284: 16369-76. PMID 19369257 DOI: 10.1074/Jbc.M109.001743  0.751
2008 Zhang H, Casasnovas JM, Jin M, Liu JH, Gahmberg CG, Springer TA, Wang JH. An unusual allosteric mobility of the C-terminal helix of a high-affinity alphaL integrin I domain variant bound to ICAM-5. Molecular Cell. 31: 432-7. PMID 18691975 DOI: 10.1016/J.Molcel.2008.06.022  0.312
2008 Hu X, Kang S, Chen X, Shoemaker CB, Jin MM. Yeast surface 2-hybrid to detect protein-protein interactions via the secretory pathway as a platform for antibody discovery Nature Precedings. 3: 1-1. DOI: 10.1038/Npre.2008.2067.1  0.75
2006 Jin M, Song G, Carman CV, Kim YS, Astrof NS, Shimaoka M, Wittrup DK, Springer TA. Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. Proceedings of the National Academy of Sciences of the United States of America. 103: 5758-63. PMID 16595626 DOI: 10.1073/Pnas.0601164103  0.367
Show low-probability matches.